19730-75-7

Basic information

• Product Name: 5'-deoxypyridoxal 5'-methylenephosphonic acid
• Synonyms: 5'-deoxypyridoxal 5'-methylenephosphonic acid
• CAS NO: 19730-75-7
• Molecular Formula: C9H12NO5P
• Molecular Weight: 245.169041
• Mol File: 19730-75-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 573.3°Cat760mmHg
• Flash Point: 300.5°C
• Appearance: /
• Density: 1.522g/cm³
• CAS DataBase Reference: 5'-deoxypyridoxal 5'-methylenephosphonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-deoxypyridoxal 5'-methylenephosphonic acid(19730-75-7)
• EPA Substance Registry System: 5'-deoxypyridoxal 5'-methylenephosphonic acid(19730-75-7)

Safety Data

• Hazardous Substances Data: 19730-75-7(Hazardous Substances Data)

Upstream product

• 65-23-6 5-hydroxy-6-methyl-3,4-pyridinedimethanol 
• 1136-52-3 (2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)methanol 
• 6560-65-2 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridine-5-carboxaldehyde 

Relevant articles and documents

Pyridoxal phosphate. I. Phosphonic acid analogs of pyridoxal phosphate. Synthesis via Wittig reactions and enzymic evaluation.

-

Synthesis of hydrolysis-resistant pyridoxal 5′-phosphate analogs and their biochemical and X-ray crystallographic characterization with the pyridoxal phosphatase chronophin

A set of phosphonic acid derivatives (1-4) of pyridoxal 5′-phosphate (PLP) was synthesized and characterized biochemically using purified murine pyridoxal phosphatase (PDXP), also known as chronophin. The most promising compound 1 displayed primarily competitive PDXP inhibitory activity with an IC50 value of 79 μM, which was in the range of the Km of the physiological substrate PLP. We also report the X-ray crystal structure of PDXP bound to compound 3, which we solved to 2.75 ? resolution (PDB code 5AES). The co-crystal structure proves that compound 3 binds in the same orientation as PLP, and confirms the mode of inhibition to be competitive. Thus, we identify compound 1 as a PDXP phosphatase inhibitor. Our results suggest a strategy to design new, potent and selective PDXP inhibitors, which may be useful to increase the sensitivity of tumor cells to treatment with cytotoxic agents.